Price
No data yet.
Social Signal Score
Analyst Ratings
10 analystsRevenue
$1.16MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Arthur Kuan
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 142
- Beta
- 0.24
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 62.83
Financials
Revenue
$1.16M+496.4%Net Income
$-79.06MEBITDA
$-79.06MFree Cash Flow
$-46.88MEPS (diluted)
$-0.90Shares Outstanding (diluted)
88.20M+32.4%Operating Expenses
$83.63MCash & Debt
$1.03BRevenue by Segment (annual)
$806.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $4.04M | $-161.00M | $-2.08 |
| 2024 | $1.14M | $-88.04M | $-1.41 |
| 2023 | $204.0K | $-48.61M | $-1.02 |
| 2022 | $191.0K | $-35.44M | $-0.66 |
| 2021 | $10.36M | $-12.84M | $-0.28 |
Valuation
CGONhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120-2.70%Social Signal Score
Mentions (4)
- Newsseekingalpha.com·21d ago·Positive
CG Oncology, Inc. (CGON) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript CG Oncology, Inc. (CGON) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·34d ago·Neutral
CG Oncology to Present at Upcoming Investor Conferences in September DALLAS, Sept. 02, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat presentations at the Cantor Fitzgerald and Morgan Stanley Global Healthcare Conferences in New York City this month. The details of the upcoming events are as follows:
View source ↗ - News (RSS)investing·47d ago·Neutral
CG Oncology stock hits all-time high of 79.5 USD
View source ↗ - Newsseekingalpha.com·53d ago·Positive
CG Oncology: Circling Back After Huge Rally CG Oncology is advancing cretositimogene grenadenorepvec (cret) for NMIBC, showing strong efficacy and best-in-class safety versus competitors. Cret achieved a 75% anytime CR, 46% 12-month CR, and 42% 24-month CR in BOND-003 Cohort C, with no Grade 3+ adverse events. Rolling BLA for cret in HR BCG-unresponsive NMIBC is expected to complete in 4Q26, with multiple trial readouts in 2H26 and 2027.
View source ↗
Earnings
Fri, Nov 13(in 5 weeks)
Consensus estimate $-0.86 per share
Typical surprise -15.4% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.90 vs $-0.66miss
- Fri, May 8$-0.71 vs $-0.58miss
- Fri, Feb 27$-0.51 vs $-0.61beat
- Fri, Nov 14$-0.57 vs $-0.56miss
- Fri, Aug 8$-0.54 vs $-0.49miss
- Tue, May 13$-0.45 vs $-0.39miss
Estimates and results for CGON via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CGON officers and directors.
- Bought
- $74.8m
- Sold
- $10.3m
2 trades
29 trades
- Post Leonard Esold
- Post Leonard Esold
- Post Leonard Esold
- Mulay Jamessold
- Liu Brian Guan-chyunbought
- Post Leonard Esold
- Post Leonard Esold
- Mulay Jamessold
69 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CGON.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.